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We read with interest the accepted paper by de Jonge and colleagues [1] examining possible 
mechanisms behind the commonly observed phenomenon of a gradual decrease in tacrolimus 
dose-requirements and increase in dose-corrected whole blood exposure following kidney 
transplantation. We were pleased to see that they have added confirmation of our explanation 
of how haematocrit and steroid dose can account for observed changes in tacrolimus whole 
blood clearance [2] but were surprised they had not mentioned this in their publication. 
 
Results reported by de Jonge et al. of 65 patients are generally in agreement with our findings 
from building a theory-based population pharmacokinetic model of tacrolimus in 242 adult 
kidney transplant recipients [2]. In our study we found that a model that accounted for 
differences in tacrolimus whole blood concentrations due to haematocrit variation, via 
estimation of tacrolimus plasma concentration, was superior to empirical use of haematocrit 
as a covariate for whole blood clearance. De Jonge et al. have not clearly described how they 
used haematocrit but it seems they may have used an empirical approach. The empirical 
approach leads to misspecification of the pharmacokinetic model because the influence of 
haematocrit is only on clearance and not both volume and clearance as expected in theory. 
 
During modelling we tested different approaches to describe the possible induction effect of 
prednisolone, on CYP3A isoenzymes and/or P-glycoprotein in the small intestine and/or 
liver, on tacrolimus pharmacokinetics. Such an effect could theoretically lead to altered 
tacrolimus bioavailability and/or plasma clearance. A model based on decreasing tacrolimus 
bioavailability rather than increasing unbound tacrolimus clearance with increasing 
prednisolone dose was found to be slightly superior. In our study the maximum reduction in 
tacrolimus bioavailability caused by use of prednisolone was estimated to be -67% (95% CI -
41%, -89%) and the prednisolone daily dose exerting half maximum effect was estimated to 
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be 35mg (95% CI 7mg, 50mg). Additionally, tacrolimus plasma clearance was estimated to 
be 30% higher and bioavailability 18% lower in CYP3A5*1 carriers (CYP3A5 expressers) 
compared to CYP3A5*3/*3 homozygous patients (CYP3A5 non-expressers).  
 
The population model that we developed allowed for a corticosteroid inductive effect in all 
individuals (not just CYP3A5 non-expressers). This could be an important consideration if 
the inductive effect corticosteroids have is on P-glycoprotein as well as CYP3A isoenzymes. 
As alluded to by de Jonge et al, increased P-glycoprotein expression/activity at the apical 
membrane due to corticosteroid usage could increase tacrolimus efflux to the gut lumen, 
which might decrease tacrolimus oral bioavailability either directly or indirectly by 
increasing the access of tacrolimus to intestinal CYP3A isoenzymes [3, 4]. The net effects of 
these intestinal process could be a progressive decrease in tacrolimus oral bioavailability, 
without changes in in vivo CYP3A activity. 
 
Further research, particularly in vivo studies are required to fully elucidate the mechanisms by 
which corticosteroids and tacrolimus interact. A tacrolimus-corticosteroid interaction is likely 
to have clinically significant consequences for interpretation of concentrations and use for 
dose adjustment, especially during steroid tapering or high dose therapy for acute rejection 
after transplantation. 
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